Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Lymphoma, Malignant
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myelofibrosis
- Waldenstrom Macroglobulinemia
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02916979
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Kenneth Meehan, MD Dartmouth-Hitchcock Medical Center